Meridian Bioscience Inc. (VIVO) Holdings Increased by SG Americas Securities LLC
SG Americas Securities LLC raised its position in Meridian Bioscience Inc. (NASDAQ:VIVO) by 34.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,351 shares of the company’s stock after acquiring an additional 5,210 shares during the quarter. SG Americas Securities LLC’s holdings in Meridian Bioscience were worth $291,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in Meridian Bioscience by 9.1% in the second quarter. Vanguard Group Inc. now owns 4,018,985 shares of the company’s stock valued at $63,299,000 after acquiring an additional 334,480 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Meridian Bioscience by 16.8% in the second quarter. Dimensional Fund Advisors LP now owns 1,667,971 shares of the company’s stock valued at $26,271,000 after purchasing an additional 240,143 shares during the period. Bank of New York Mellon Corp raised its position in shares of Meridian Bioscience by 1.0% in the third quarter. Bank of New York Mellon Corp now owns 871,560 shares of the company’s stock valued at $12,463,000 after purchasing an additional 8,377 shares during the period. Fred Alger Management Inc. raised its position in shares of Meridian Bioscience by 0.4% in the second quarter. Fred Alger Management Inc. now owns 620,591 shares of the company’s stock valued at $9,774,000 after purchasing an additional 2,200 shares during the period. Finally, Northern Trust Corp raised its position in shares of Meridian Bioscience by 1.6% in the second quarter. Northern Trust Corp now owns 557,398 shares of the company’s stock valued at $8,780,000 after purchasing an additional 8,886 shares during the period. Hedge funds and other institutional investors own 87.01% of the company’s stock.
VIVO has been the topic of several research analyst reports. Zacks Investment Research raised shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a research report on Thursday, October 5th. Canaccord Genuity reissued a “hold” rating and issued a $14.00 price objective on shares of Meridian Bioscience in a research report on Friday, October 13th. Two equities research analysts have rated the stock with a sell rating and four have issued a hold rating to the company’s stock. Meridian Bioscience presently has an average rating of “Hold” and an average target price of $11.50.
Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings data on Thursday, November 9th. The company reported $0.15 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.15. The company had revenue of $49.70 million for the quarter, compared to analyst estimates of $48.28 million. Meridian Bioscience had a net margin of 10.74% and a return on equity of 17.03%. The company’s revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.14 earnings per share. sell-side analysts predict that Meridian Bioscience Inc. will post 0.66 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, November 30th. Stockholders of record on Monday, November 20th were given a $0.125 dividend. This represents a $0.50 annualized dividend and a dividend yield of 3.51%. The ex-dividend date was Friday, November 17th. Meridian Bioscience’s payout ratio is presently 98.04%.
About Meridian Bioscience
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience Inc. (NASDAQ:VIVO).
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.